Biocon Ltd share price
Biocon Ltd (BIOCON) is a stock listed on India's exchanges (NSE & BSE). It is commonly tracked under the Pharma theme. On Traddx you can view its live price, interactive candlestick charts with 20/50/200-day moving averages and golden/death-cross detection, quarterly results, analyst price targets, peer comparison, and the smart-money signal — which star investors hold it and who is buying it on today's bulk/block deals tape.
Biocon Limited value chain — customers, suppliers & competitors
Biocon Limited is a leading Indian biopharmaceutical company that manufactures complex generic formulations, biosimilars, and provides contract research services through its subsidiary Syngene.
🛒 Customers — who buys from Biocon Limited
- Viatris — Biosimilars and complex biologic formulations
- Global Healthcare Distributors and Hospitals — Generic injectables and insulins
⛓️ Suppliers — raw materials & inputs
- Chemical and Raw Material Suppliers — Solvents, biochemicals, and media for fermentation
- Packaging Material Vendors — Vials, syringes, and cold-chain packaging
⚔️ Competitors — other sellers
- Dr. Reddy's Laboratories — Competes in global biosimilars, generic formulations, and active pharmaceutical ingredients.
- Cipla — Competes in respiratory and complex generic medications globally.
- Sun Pharmaceutical Industries — Largest Indian pharma peer, competing across specialty medicines and generics.
- Lupin — Competes in global generic drug markets and complex formulations.
🔀 Other suppliers to its customers
- Dr. Reddy's Laboratories — Provides alternative biosimilars and generic products to global markets.
- Sun Pharmaceutical Industries — Supplies competing generic and specialty drugs worldwide.
🤝 Peers that share its suppliers
- Dr. Reddy's Laboratories — Buys similar specialty chemicals and packaging materials for drug manufacturing.
- Cipla — Shares common raw material and laboratory reagent suppliers for pharma production.
This value-chain map is AI-researched from public sources; company links and any figures are estimates, not official company disclosures. Not investment advice.